Content
05/14/2025
Sacramento, CA USA
Therini Bio
completed $39 million Series A Round funding. Investors include
Angelini Ventures, Apollo Health Ventures, SV Health Investors, Dementia Discovery Fund, MRL Ventures Fund, Sanofi Ventures, Eli Lilly and Company, Dolby Family Ventures, Foundation For A Better World.
About
Therini Bio is a clinical-stage biotech company developing immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. Therini Bio is developing a pipeline of potential first-in-class therapies selectively targeting toxic fibrin accumulation for diseases, including Alzheimer’s disease and Diabetic Macular Edema, where destructive neuroinflammation plays a central role in the disease process.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
